Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk‐based prenatal screening for trisomy 18 using alpha‐fetoprotein, unconjugated oestriol and human chorionic gonadotropin

1 Aug 1995

Abstract excerpt

Nine centres collaborated to examine the feasibility of a screening method for trisomy 18 that was based on assigning individual risk, using a combination of maternal age and measurements of alpha-fetoprotein (AFP), unconjugated oestriol (uE3), and human chorionic gonadotropin (hCG). Second-trimester measurements of these analytes were obtained from 94 trisomy 18 pregnancies. In the 89 pregnancies without an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fetal and Pediatric Neurological Disorders
Share to Parvovirus B19 Infection Studies
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 7479589
DOI: 10.1002/pd.1970150806

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk‐based prenatal screening for trisomy 18 using alpha‐fetoprotein, unconjugated oestriol and human chorionic gonadotropinPMID 7479589Read ↗

Prospective intervention trial of a screening protocol to identify fetal trisomy 18 using maternal serum alpha‐fetoprotein, unconjugated oestriol, and human chorionic gonadotropinSemantic proximity Read ↗

Appropriate biochemical parameters in first-trimester screening for Down syndromeSemantic proximity Read ↗

UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group.Semantic proximity Read ↗

First‐trimester biochemical screening for fetal chromosome abnormalities and neural tube defectsSemantic proximity Read ↗

Prenatal Screening for Down's Syndrome with Use of Maternal Serum MarkersSemantic proximity Read ↗

Second trimester serum tests for Down's Syndrome screeningSemantic proximity Read ↗

A New Approach to Calculating the Risk of Chromosomal Abnormalities with First-Trimester Screening DataSemantic proximity Read ↗

Screening for trisomy 18 by maternal age, fetal nuchal translucency, free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐ASemantic proximity Read ↗

Predictive value of the triple screening test for the phenotype of Down syndrome.Semantic proximity Read ↗

Fetal choroid plexus cysts and trisomy 18: Assessment of risk based on ultrasound findings and maternal ageSemantic proximity Read ↗

Screening of Maternal Serum for Fetal Down's Syndrome in the First TrimesterSemantic proximity Read ↗

Second‐trimester double or triple screening for Down syndrome: A comparison of Chinese and Caucasian populationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.